Novo Nordisk claims late-stage MASH victory, continuing GLP-1’s expansion

A day af­ter Madri­gal Phar­ma­ceu­ti­cals im­pressed in­vestors, No­vo Nordisk is look­ing to steal the spot­light.

The Dan­ish drug­mak­er re­port­ed Fri­day that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.